Organic Chemistry TRIZ Cases

Phthalate-free electron donors modify catalyst parameters to improve hydrogen response and lower xylene solubles in polyolefin polymerization.

Replacing m-CPBA with hypervalent iodine oxidants enables over 50% pentazolate formation and simpler liquid-liquid extraction for scale-up.

A color-changing indicator screens impurities in mercapto heterocyclic compounds before distillation or active-carbon purification.

Replacing hazardous pyridine, 1-alkylimidazole-based ionic liquids enable clear-solution esterification, easier purification, and minimal residual solvent.

A fluorine-containing ether lubricant forms a uniform, adherent layer that supports thinner magnetic media while resisting wear and corrosion.

Hydroporphyrins offer narrow emission but weak 405 nm absorption; linked porphyrin dyads address this excitation and brightness bottleneck.

Polymer-bound onium salt monomers keep acid generation localized, balancing EUV sensitivity with reduced acid diffusion for lower LWR and better CDU.

This case examines fused bicyclic pyrazoles that lower RBP4 levels by at least 50% within 24 hours for metabolic disease treatment.

With current neuromuscular treatments limited, these compounds target the skeletal sarcomere troponin complex to modulate contractility.

Thianthrenium salts enable positional-selective aromatic C–H functionalization without directing groups, reducing constitutional-isomer mixtures.

Separate furfural from contaminated wood-based streams with hetero-azeotropic distillation, decanter phase splitting, and aqueous reflux.

A staged annulation uses an organic base, followed by ammonia or an ammonium salt, to produce sulfur-containing pyridine building blocks in high yield.

Hydrophilic groups add water solubility to beta-amyloid imaging compounds, enabling injectable retinal detection while preserving selective binding.

Curable fluorenyl compounds form stable OLED thin films from coating solutions, reducing deposition material loss and supporting large-area manufacturing.

CCNE1 amplification can increase CDK2 activity and undermine CDK4/6 therapy; selective inhibitors target this resistance mechanism.

See how pharmacological compounds induce endogenous γ-globin to support HbF production for sickle cell disease and β-thalassemia treatment.

Specific substituents in an organic OLED compound help lower driving voltage while improving efficiency and extending device service life.

A specific amine compound in the hole transport region improves luminous efficiency and extends light-emitting element service life.

Mutant FLT3 can drive AML relapse despite conventional treatment; this case uses a piperidine derivative to inhibit wild-type and mutant FLT3.

Combining a fluorophore with a radiolabel enables preoperative detection and intraoperative guidance while reducing non-target uptake.

Continuous water removal keeps the reaction mixture below 1.5 wt.% water, improving hydroxylation rate, yield, and selectivity.

Metal-free TADF emitters address the OLED trade-off between blue-to-green efficiency and device stability through donor–acceptor molecular design.

For pyrazole carboxylate synthesis, excess phosphorus tribromide and bromine generate the brominating species in situ, avoiding reactor coating and enabling 90–95% yields.

Molecular substituents improve electron injection and mobility while limiting crystallization, supporting efficient, stable OLEDs at low driving voltage.

Multiple iodine atoms boost light absorption, while phenolic groups support acid generation and dissolution contrast for fine photoresist patterns.

Reducing polysorbate ester groups to ethers creates surfactants that resist hydrolysis and enzymatic degradation across changing pH conditions.

An aqueous acid mixture forms stable passivate films on zinc coatings without hexavalent chromium for corrosion resistance.

Variable R1–R5 substituents tune dimethylsulfoximine derivatives for NLRP3 inhibition, oral bioavailability, and inflammatory disease treatment.

A radical-polymerizable group and 13-position cyclic structure help limit elution while improving color density and fading speed.

Strategic heterocyclic structure changes address insufficient OLED charge mobility and lifespan by tuning organic compounds for transport and stability.

Matriptase-2 activity can suppress hepcidin and impair iron metabolism; inhibitor compounds target this pathway in IRIDA.

See how stereodefined thienopyrimidine derivatives target ACC1 and ACC2 to address limited therapies for obesity, diabetes, and fatty liver disease.

Immobilizing palladium nanoparticles on porous COF-701 addresses catalyst separation and recyclability during CO₂-to-cyclic-carbonate conversion.

Formula I compounds selectively inhibit Factor XI activation to address inadequate thrombosis treatment while supporting improved pharmacokinetic profiles.

A Formula 1 host and two dopants use ordered energy levels to improve emission efficiency and extend light-emitting device lifespan.

Fc or albumin-linked neuraminidase inhibitors extend circulation and engage immune cells to address prolonged influenza shedding.

PD-L1 targeting compounds address limited treatment efficacy by enhancing immune response and suppressing HBV and HDV replication.

Solid graphene particles carried in stearic, palmitic, or oleic acid avoid dust and solvents while dispersing graphene homogeneously in polymers.

Hydroxy-functionalized triazines act as crosslinking agents for amorphous fluorinated polymers, improving cure efficiency and article properties.

Selective purine derivatives address inadequate SIK3 treatments by inhibiting SIK3 while avoiding PI3K isoform activity in cancer and autoimmune disease.

Water-soluble ODSO compounds replace conventional acids while converting DSO by-products into a refining-useful acid medium.

Toxic or unstable RNA probes are replaced by N3-kethoxal derivatives that reversibly label single-stranded guanine in live cells.

Localized substitutions and ring-size changes tune fused mescaline derivatives for 5-HT receptors and dopamine transporters while addressing panic, paranoia, and nausea.

Compounds disrupt KLF10-DNA binding to reduce tumor-site T regs and enhance anti-tumor immune responses.

Dihydrochloric and dibenzenesulfonic salts improve c-Met inhibitor solubility and crystalline properties for pharmaceutical use.

Low electron mobility and crystallization in OLED transport layers are addressed with twisted spiro compounds that improve injection and film stability.

Hydroxylation-induced collapse activates CYP1B1 prodrugs in cancer cells, releasing cytotoxic or diagnostic molecules while limiting toxicity in normal tissues.

Small-molecule compounds target or degrade BRM to exploit synthetic lethality in BRG1-deficient cancers, including potential lung cancer treatments.

Novel fluoroolefins address the tradeoff between efficient electronics heat transfer and high GWP, supporting non-flammable cooling fluids.

Mild aqueous, room-temperature synthesis protects bioactive agents while acidic-pH matrix degradation enables controlled release.

A compound in the emission-auxiliary layer lowers driving voltage and increases luminous efficiency.

A latent reducing agent enables low-temperature cationic polymerization of epoxy resins.

Controlled diol conductivity reduces thermal weight loss, enabling high-speed molding while maintaining mechanical properties and color tone.

A perfluoropolyether acyl friction modifier enhances lubrication in fluorine oil and grease without precipitation.

Selective EP4 antagonists reduce cardiovascular side effects by targeting joint inflammation pathways without affecting other prostaglandin receptors.

Antioxidants co-distill with crude isosorbide to protect against auto-oxidation during dehydration processing.

Freezing below minus 45 C prevents crystalline contamination during storage, resolving stability reliability contradictions.

Doped arylamine compounds enhance hole injection to resolve heat resistance trade-offs in organic electroluminescent devices.

Triple bonds in oxazine compounds raise decomposition temperatures above 350°C while reducing linear expansion coefficients.

Formula I compound inhibits IDO and TDO to disrupt tryptophan metabolism.

Replacing hazardous sodium amide with safer reagents during cyclization and resolution improves chemical purity and yield.

A viologen-based electrochromic compound delivers uniform black coloring through integrated electrolyte photocuring.

Melamine oxalate compounds enable cool-burning gas generation below 1700 K, reducing heat sink weight while maintaining sufficient work impulse.

Nitrogen-oxygen substituted organic compounds optimize energy transfer to reduce driving voltage while extending device lifespan.

Pyrridinobenzodiazepine dimers form covalent DNA adducts to interfere with replication, reducing adverse effects seen in existing therapies.

Converting the liquid intermediate to a crystalline trihydrate enables filtration purification, removing impurities that degrade pimavanserin yield.

Rigid aromatic network organic electroluminescent compounds facilitate fast electron current properties through intermolecular stacking.

A host luminescent material with a short conjugated chain enhances triplet energy levels and molecular weight for organic electroluminescent devices.

Acylation modifies metformin structure to reduce gastrointestinal adverse events while maintaining glucose lowering efficacy.

A protective coating film prevents electrolyte decomposition and corrosion, maintaining battery life characteristics at high voltages.

Lower transverse element and legs compress against vehicle structure to absorb impact energy, reducing longitudinal overhang.

Hydroxamate GCPII inhibitor prodrugs mask polar groups with hydrophobic moieties to enhance membrane permeation, resolving poor oral bioavailability.

Ladder-type compounds with condensed rings and heteroatoms enable balanced charge transport, reducing operational voltage and extending device lifetime.

Novel biaryl piperidine amide compounds modulate store-operated calcium entry through specific molecular substitutions.

Form alpha provides chemical stability for large-scale manufacturing, resolving scalability bottlenecks in current polymorphic synthesis methods.

An amine-based compound with dinaphthofuran groups enhances hole transport in organic light-emitting devices.

Imidazole-carbazole compounds enhance OLED efficiency and lifetime by optimizing molecular structure for better charge transport.

Solvent swap and decarboxylation extract Δ9-THC from cannabis flowers, avoiding reverse phase columns to improve yield.

A continuous flow reactor system synthesizes artemisinin using singlet oxygen photooxidation of dihydroartemisinic acid.

Direct esterification and Dieckmann reaction synthesize Dolasetron without protective groups, reducing residues.

Twisted aryl-N groups in triarylamine compounds raise triplet energy levels to reduce luminescence quenching in green, blue-green, and blue emitters.

Amide bonds in the fluorine ether compound improve chemical substance resistance and wear resistance at reduced thickness.

Hetero ring structures improve charge mobility to boost luminance and emission lifespan while maintaining low voltage operation.

Formula I compounds inhibit tumor cell growth across gastric, colon, and breast cancer types.

A novel organic compound featuring a fluorene core enhances charge carrier injection and transport within organic electroluminescent devices.

Substituted pyrrolidine-2-carboxamide compounds inhibit the MDM2-p53 protein-protein interaction to accumulate p53 and induce apoptosis.

Extended lipophilic side chains in substituted chroman-6-ols prevent spontaneous combustion during marine transport.

Atropisomeric compounds improve OLED longevity by isolating specific isomers to ensure reproducible production and stable sublimation.

Targeted inhibitors block O-GlcNAcase activity, preventing tau hyperphosphorylation and avoiding off-target effects from non-selective agents.

An asymmetric pyrimidine compound enhances operational stability and efficiency by suppressing crystallization within the device structure.

Arylamine compounds improve hole injection and transport, preventing crystallization to extend device lifespan.

Carbonyl ylide [3+2] cycloaddition synthesizes platensimycin derivatives that inhibit bacterial fatty acid synthesis, addressing multi-drug resistance.